Lifecore Net Income Applicable To Common Shares from 2010 to 2025

LFCR Stock   6.13  0.11  1.83%   
Lifecore Biomedical Net Loss yearly trend continues to be relatively stable with very little volatility. Net Loss is likely to grow to about -87.4 M this year. Net Loss is the net income that remains after preferred dividends have been deducted, available to common shareholders. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-92 M
Current Value
-87.4 M
Quarterly Volatility
44.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lifecore Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lifecore Biomedical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.4 M, Interest Expense of 21.8 M or Total Revenue of 140.1 M, as well as many indicators such as Price To Sales Ratio of 0.2, Dividend Yield of 0.0 or PTB Ratio of 0.74. Lifecore financial statements analysis is a perfect complement when working with Lifecore Biomedical Valuation or Volatility modules.
  
Check out the analysis of Lifecore Biomedical Correlation against competitors.
To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.

Latest Lifecore Biomedical's Net Income Applicable To Common Shares Growth Pattern

Below is the plot of the Net Income Applicable To Common Shares of Lifecore Biomedical over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Lifecore Biomedical's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lifecore Biomedical's overall financial position and show how it may be relating to other accounts over time.
Net Income Applicable To Common Shares10 Years Trend
Slightly volatile
   Net Income Applicable To Common Shares   
       Timeline  

Lifecore Net Income Applicable To Common Shares Regression Statistics

Arithmetic Mean(34,269,466)
Coefficient Of Variation(130.95)
Mean Deviation39,216,082
Median411,000
Standard Deviation44,875,930
Sample Variance2013.8T
Range102.6M
R-Value(0.86)
Mean Square Error548.2T
R-Squared0.75
Significance0.000016
Slope(8,140,908)
Total Sum of Squares30207.7T

Lifecore Net Income Applicable To Common Shares History

2025-87.4 M
2024-92 M
2022-102.2 M
2021-97.4 M
2020-32.7 M
2019-38.2 M

About Lifecore Biomedical Financial Statements

Lifecore Biomedical shareholders use historical fundamental indicators, such as Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although Lifecore Biomedical investors may analyze each financial statement separately, they are all interrelated. The changes in Lifecore Biomedical's assets and liabilities, for example, are also reflected in the revenues and expenses on on Lifecore Biomedical's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-92 M-87.4 M

Additional Tools for Lifecore Stock Analysis

When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.